The ACUITY trial was a prospective, randomised open-label, trial of bivalirudin with or without GPIIb/ IIIa inhibitor (Arms B and C respectively) versus unfractionated heparin or enoxaparin with GPIIb/ IIIa inhibitor (Arm A) in 13,819 high risk ACS patients.